1. Scrip
  2. >>Business

Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T

200 Jobs Shed And Pipeline Cut Back

 
• By Andrew McConaghie

The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.

Cocoon
Galapagos has acquired Cellpoint and its point-of-care manufactured CAR-T technology called 'Cocoon'. • Source: Galpagos

After a string of failed drug candidates from its in-house R&D, Galapagos CEO Paul Stoffels has unveiled a new focus on immunology and oncology for the company, along with plans for more acquisitions and in-licensing.

The new strategy will see two former core areas of research, fibrosis and kidney disease, abandoned and the shedding of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.